Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1350

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Datopotamab deruxtecan
DRUG: Durvalumab
DRUG: Carboplatin
DRUG: Pembrolizumab
DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Paclitaxel

Sponsor

AstraZeneca